January 22, 2018 7:26pm
HSGX closed at $2.56 – an 8.2% discount, not bad with anticipated proceeds of $5.5 M
In connection with the offering, Histogenics granted the underwriter a 30-day option to purchase up to an additional 351,064 shares of common stock.
The offering is expected to close on or about January 25, 2018, subject to customary closing conditions. The gross proceeds to Histogenics from this offering are expected to be $5,500,010.50, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics.
Certain entities affiliated with directors of Histogenics may purchase shares of common stock in the offering at $2.56, today’s closing price of our common stock on The NASDAQ Capital Market.
Canaccord Genuity is acting as the sole book-running manager for the offering.